Acquired Factor VIII Inhibitors: Pathophysiology and Treatment
- 1 January 2006
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2006 (1), 432-437
- https://doi.org/10.1182/asheducation-2006.1.432
Abstract
Hemophilia A is classically caused by a congenital deficiency of factor VIII, but an acquired form due to inhibitors to factor VIII (FVIII) typically presents later in life. Patients who develop such acquired factor VIII inhibitors may present with catastrophic bleeding episodes, despite having no prior history of a bleeding disorder. Though the disorder is rare, it is known to cause significant morbidity and mortality. This review will focus on what is currently known about acquired hemophilia A, its pathogenesis, its associated etiologies, and its treatment.Keywords
This publication has 64 references indexed in Scilit:
- Anti-factor VIII antibodiesThrombosis and Haemostasis, 2005
- The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99Journal of Thrombosis and Haemostasis, 2004
- Acquired anti‐FVIII inhibitors in childrenHaemophilia, 2002
- 1 Acquired haemophiliaBailliere's Clinical Haematology, 1998
- 9 Acquired inhibitorsBailliere's Clinical Haematology, 1996
- Use of porcine factor VIII in the treatment of patients with acquired hemophiliaBlood, 1993
- Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralizationBlood, 1989
- Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments.Proceedings of the National Academy of Sciences, 1985
- The Mode of Action of Antibodies which Destroy Factor VIIIBritish Journal of Haematology, 1972
- CIRCULATING ANTICOAGULANTSMedicine, 1961